valproic acid has been researched along with Atherosclerotic Parkinsonism in 20 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Combination therapy with valproic acid plus quetiapine is recommended as one of the first-line approaches to treatment of manic or mixed episodes in patients with bipolar disorder." | 3.77 | Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine. ( De Dios, C; Fudio, S; Lorenzo, A, 2011) |
| "We describe two patients who developed levodopa-responsive parkinsonism without dementia at least 4 years after beginning chronic valproate (VPA) treatment for seizures." | 3.70 | Reversible parkinsonism induced by prolonged treatment with valproate. ( Onofrj, M; Paci, C; Thomas, A, 1998) |
| " Reduction in VPA dosage in the third patient produced no improvement." | 2.71 | Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. ( Clough, P; Duncan, S; Easterford, K; Fallon, K; Kellett, M, 2004) |
| " We hypothesise that an increase in valproate dosage unmasked clinically silent Parkinson's disease." | 1.42 | Clinically silent idiopathic Parkinson's disease unmasked by valproate use: a brief report. ( Athauda, D; Batley, R; Ellis, C, 2015) |
| "Valproic acid is a drug used for the treatment of a variety of psychiatric and neurological disorders." | 1.39 | Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia. ( Factor, SA; Silver, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lai, CL | 1 |
| Lu, CC | 1 |
| Lin, HC | 1 |
| Sung, YF | 1 |
| Wu, YP | 1 |
| Hong, JS | 1 |
| Peng, GS | 1 |
| Silver, M | 1 |
| Factor, SA | 1 |
| Athauda, D | 1 |
| Batley, R | 1 |
| Ellis, C | 1 |
| Salazar, Z | 1 |
| Tschopp, L | 1 |
| Calandra, C | 1 |
| Micheli, F | 1 |
| Schreur, L | 1 |
| Middeljans-Tijssen, CW | 1 |
| Hengstman, GJ | 1 |
| Olde Rikkert, MG | 1 |
| Monti, B | 1 |
| Gatta, V | 1 |
| Piretti, F | 1 |
| Raffaelli, SS | 1 |
| Virgili, M | 1 |
| Contestabile, A | 1 |
| Louter, M | 1 |
| Tromp, SC | 1 |
| Sleegers, MJ | 1 |
| Beutler, JJ | 1 |
| Hardon, WJ | 1 |
| Berden, JH | 1 |
| Verhave, JC | 1 |
| Conemans, JM | 1 |
| Hollander, DA | 1 |
| Dautzenberg, PL | 1 |
| Hoogeveen, EK | 1 |
| De Dios, C | 1 |
| Fudio, S | 1 |
| Lorenzo, A | 1 |
| Levin, OS | 1 |
| Shindriaeva, NN | 1 |
| Anikina, MA | 1 |
| Easterford, K | 1 |
| Clough, P | 1 |
| Kellett, M | 1 |
| Fallon, K | 1 |
| Duncan, S | 1 |
| Gaubert, ML | 1 |
| Cougnaud, A | 1 |
| Ghali, A | 1 |
| Bruhat, C | 1 |
| Diquet, B | 1 |
| Berrut, G | 1 |
| Ristić, AJ | 1 |
| Vojvodić, N | 1 |
| Janković, S | 1 |
| Sindelić, A | 1 |
| Sokić, D | 1 |
| Friis, T | 1 |
| Christensen, TR | 1 |
| Gerlach, J | 1 |
| Froomes, PR | 1 |
| Stewart, MR | 1 |
| Alvarez-Gomez, MJ | 1 |
| Vaamonde, J | 1 |
| Narbona, J | 1 |
| Barao, M | 1 |
| Barona, P | 1 |
| Brannan, T | 1 |
| Gudin, M | 1 |
| Ibañez, R | 1 |
| Wils, V | 1 |
| Golüke-Willemse, G | 1 |
| Park-Matsumoto, YC | 1 |
| Tazawa, T | 1 |
| Onofrj, M | 1 |
| Thomas, A | 1 |
| Paci, C | 1 |
| van der Zwan, A | 1 |
1 review available for valproic acid and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
[Valproate induced parkinsonism].
Topics: Aged; Anticonvulsants; Epilepsy; Female; Humans; Male; Parkinson Disease, Secondary; Valproic Acid | 1998 |
1 trial available for valproic acid and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Incidence; Male; Middle Aged; | 2004 |
18 other studies available for valproic acid and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Valproate is protective against 6-OHDA-induced dopaminergic neurodegeneration in rodent midbrain: A potential role of BDNF up-regulation.
Topics: Animals; Brain; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Dopaminergic Neurons; Mal | 2019 |
Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Diseas | 2013 |
Clinically silent idiopathic Parkinson's disease unmasked by valproate use: a brief report.
Topics: Aged; Humans; Male; Parkinson Disease, Secondary; Valproic Acid | 2015 |
Pisa syndrome and parkinsonism secondary to valproic acid in Huntington's disease.
Topics: Aged; Anticonvulsants; Humans; Huntington Disease; Male; Parkinson Disease, Secondary; Sensation Dis | 2008 |
[Cognitive impairment and parkinsonism due to use of sodium valproate].
Topics: Aged; Anticonvulsants; Cognition Disorders; Epilepsy; Humans; Male; Parkinson Disease, Secondary; Re | 2009 |
Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Brain; Cell Death; Chromatography, High Pressure Liq | 2010 |
[Parkinsonism due to the medication].
Topics: Aged; Aged, 80 and over; Cinnarizine; Female; Humans; Parkinson Disease, Secondary; Valproic Acid | 2009 |
Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus.
Topics: Aged; Anticonvulsants; Dementia; Diagnosis, Differential; Disease Progression; Epilepsy, Generalized | 2010 |
Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Cognition Disorders; Cytochrome P-450 CYP3A; Dibenzothiaze | 2011 |
[Drug-induced parkinsonism].
Topics: Anticonvulsants; Antipsychotic Agents; Calcium Channel Blockers; Cinnarizine; Diagnosis, Differentia | 2012 |
Loss of autonomy related to valproic acid intake.
Topics: Aged, 80 and over; Cognition Disorders; Humans; Male; Parkinson Disease, Secondary; Valproic Acid | 2006 |
The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Cognition Disorders; Drug Administration Schedule; Drug Th | 2006 |
Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Biperiden; Double-Blind Method; Drug Therapy, Combina | 1983 |
A reversible parkinsonian syndrome and hepatotoxcity following addition of carbamazepine to sodium valproate.
Topics: Aged; Carbamazepine; Chemical and Drug Induced Liver Injury; Cholestasis; Drug Interactions; Drug Th | 1994 |
Parkinsonian syndrome in childhood after sodium valproate administration.
Topics: Child; Female; Humans; Parkinson Disease, Secondary; Valproic Acid | 1993 |
Extrapyramidal syndrome due to valproate administration as an adjunct to lithium in an elderly manic patient.
Topics: Aged; Antimanic Agents; Basal Ganglia Diseases; Bipolar Disorder; Drug Therapy, Combination; Female; | 1997 |
Reversible parkinsonism induced by prolonged treatment with valproate.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; | 1998 |
[Transient Parkinson syndrome and tremor caused by the use of sodium valproate].
Topics: Aged; Epilepsy; Female; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Valproic Acid | 1989 |